Isomab’s review of 11 historical therapeutic-angiogenesis studies found similar malignancy rates with pro-angiogenic treatment and placebo, supporting the safety rationale for preclinical ISM-001 without proving the new antibody is safe.
Abbott’s investigational TactiFlex Duo dual-energy ablation catheter delivered favorable 12-month results in the FlexPulse Global IDE study, supporting the company’s effort to secure U.S. FDA approval after receiving CE Mark in Europe.
The EFICAS study of the Aeson Total Artificial Heart achieved its primary endpoint in 72.7% of 55 severely ill patients, with 96% remaining free of disabling stroke at 180 days and 76% discharged from hospital.
A prespecified VESALIUS-CV analysis found a 20% reduction in mortality with Amgen’s Repatha among more than 12,000 high-risk adults without a previous heart attack or stroke, strengthening the case for intensive LDL lowering before the first major cardiovascular event.
Milvexian failed to reduce cardiovascular death, heart attack or ischemic stroke after acute coronary syndrome in the Phase 3 LIBREXIA ACS trial, although the drug did not increase intracranial or fatal bleeding, leaving two major Phase 3 programs to determine whether factor XIa inhibition still works in other diseases.
CTX310 sustains deep ANGPTL3, LDL and triglyceride reductions for one year after one infusion. See what the data mean for CRISPR Therapeutics.
Aficamten hits both Phase 3 ACACIA-HCM endpoints as Cytokinetics prepares an FDA filing. See what the results mean for Myqorzo growth.